Hi, I am Sahana, and I hail from Bangalore, India.
I received my Bachelors of Science majoring in biotechnology at Kent State University in Ohio. As an undergrad, I had the opportunity to work on a Senior Honors Thesis studying the effects of a beta-adrenergic antagonist on stress-induced depression. I also had the unique chance to work at the Cleveland Clinic Foundation working on glioblastoma multiforme and a circadian rhythm lab at Kent State. Upon graduation, I worked at Dr. Steven Gray’s lab at the Gene Therapy Center at the University of North Carolina.
I have now completed my first year at Vanderbilt in the IGP program. To pursue my interests in neuroscience and psychiatric disorders, I joined the lab of Dr. Brad Grueter of the Anesthesiology department. Under his guidance, I will be studying the role of the neurotransmitter serotonin in the neural circuits underlying addiction behaviors in adolescence using pharmacology, electrophysiology and behavior studies.
When I am not doing science, I enjoy the outdoors, especially kayaking. I am also a dedicated yogi and seamstress.
Nagabhushan Kalburgi S, Gray SJ. MeCP2 Gene Transfer using novel RTT-specific rAAV Vectors. (In preparation).
Nagabhushan Kalburgi S, Samulski RJ, Gray SJ. Viral Drug Delivery for CNS disorders. Advances in non-invasive drug delivery to the brain. Future Biosciences. Editor Ryan De Vooght-Johnson (2014) (in press)
Kantor B, Bailey RM, Wimberly K, Nagabhushan Kalburgi S, and Gray SJ. Methods for Gene Transfer to the Central Nervous System. Advances in Genetics, Editor Theodore Friedmann, Advances in Genetics. 2014;87:125-97.
Nagabhushan Kalburgi S, Khan NN, Gray SJ. Recent gene therapy advancements for neurological diseases. Discovery Medicine. 2013;15(81):111-9.
Mussche S, Devreese B, Nagabhushan Kalburgi S, et al. Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy. Human Gene Therapy. 2013;24(2):209-19.
Gray SJ, Nagabhushan Kalburgi S, McCown TJ, Jude Samulski R. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Therapy. 2013;20(4):450-9.
Gadalla KK, Bailey ME, Spike RC, Ross PD, Woodard KT, Kalburgi SN, Bachaboina L, Deng JV, West AE, Samulski RJ, Gray SJ, Cobb SR. Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice. Molecular Therapy. 2013;21(1):18-30.
Camp RM, Remus JL, Kalburgi SN, Porterfield VM, Johnson JD. Fear conditioning can contribute to behavioral changes observed in a repeated stress model. Behavioral Brain Research. 2012;233(2):536-44.